Immuneering Corp Class A
Research Immuneering Corp Class A (IMRX) on Bullrun: market cap USD 338.37M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIMRX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 338.37M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 17.27M
- Free cash flow-USD 16.53M
Valuation Snapshot
latest market cap is USD 338.37M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 56.02M | -USD 45.49M | n/a | -1.27 | USD 128.65M | USD 3.82M | USD 218.48M |
| FY2024 | USD 0 | -USD 61.04M | -USD 55.08M | n/a | -2.04 | USD 36.14M | USD 4.16M | USD 41.39M |
| FY2023 | USD 0 | -USD 53.47M | -USD 49.31M | n/a | -1.88 | USD 59.41M | USD 4.46M | USD 90.58M |
| FY2022 | USD 316.95K | -USD 50.51M | -USD 44.84M | 50.1% | -1.91 | USD 72.64M | USD 4.93M | USD 109.85M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 338.37M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 425.39M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 68.31M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 215.13M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 128.06M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 425.60M | n/a | n/a | n/a |
About Immuneering Corp Class A
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Immuneering Corp Class A's market cap?
Immuneering Corp Class A's market capitalization is USD 338.37M.
What does Immuneering Corp Class A do?
Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.